ONCOLYTICS BIOTECH INC — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Oncolytics reported that substantially all planned clinical sites for its REO 033 randomized trial (evaluating pelareorep + FOLFIRI + bevacizumab vs. standard-of-care alone in RAS-mutant, MSS colorectal cancer) are now activated with multiple patients enrolled. Part A targets ~60 patients with primary endpoint of objective response rate (ORR). The company expects interim Part A data by year-end 2026 based on enrollment pace. FDA alignment provides a potential regulatory path: accelerated approval based on ORR, with full approval based on progression-free survival. REO 022 showed 33% ORR vs. ~6-11% historical benchmark, 16.6-month vs. ~5.7-month median PFS, and 27.0-month vs. ~11.2-month median overall survival.
Why this rating
Mid-stage clinical progression in lead asset is material for $72M company. Interim data within ~15 months and FDA-aligned path are meaningful catalysts, though binary trial risk remains substantial.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.